An interventional study of Soterix 1x1 line tDCS low-intensity stimulator and Sham in Apraxia of Speech, sponsored by NYU Langone Health. Recruiting at 2 sites in United States. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-06-03.
Sponsored by NYU Langone Health · Not applicable, Interventional, and Treatment
The purpose of this study is to determine whether the effect of treatment for acquired speech impairment can be enhanced by combining effective behavioral treatment with non-invasive brain stimulation. Transcranial direct current stimulation (tDCS), which delivers low-intensity current to the scalp, and is a safe and well-tolerated approach that poses a non-significant risk to participants. tDCS provides low intensity neural stimulation which has been shown to facilitate motor learning in other domains of stroke rehabilitation such as arm motor learning but the potential to enhance speech motor learning has not been explored. This will be examined with a series of single-case experimental designs.
65 studies on the registry are indexed under Apraxias; 21 are open to participants now.
This study's planned enrollment of 24 is below the median of 32 across 50 interventional studies indexed under Apraxias.
Browse Apraxias studies →NYU Langone Health is the lead sponsor of 1,430 studies on the registry; 258 are open to participants now.
Of its 235 completed or terminated interventional studies of FDA-regulated products, 197 (84%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
crossover design such that each participant receives behavioral treatment twice - once with active stimulation and once with sham stimulation - in order to evaluate differences in improvement based on treatment condition.
Device: Soterix 1x1 line tDCS low-intensity stimulator · Device: Sham
crossover design such that each participant receives behavioral treatment twice - once with active stimulation and once with sham stimulation - in order to evaluate differences in improvement based on treatment condition.
Device: Soterix 1x1 line tDCS low-intensity stimulator · Device: Sham
Introduction of the independent variable (treatment) across three different points in time. Participants will be randomly assigned to have each treatment phase begin after 3, 4, or 6 baseline sessions. This current stimulates the cortex, with anodal stimulation leading to a depolarized state in which neurons are more likely to fire.
Also known as: Soterix
Patients will have two electrodes applied (one anode, one cathode) administering no stimulation
Change in accuracy in recordings from tasks from baseline to post treatment
Subjects will be given speech production tasks. Recordings of tasks will be scored for accuracy to measure speech motor learning
Time frame: Baseline, 6 Months
Started Jan 2019 (actual). Primary completion is estimated for Apr 2027, 99 months after the start.
Of 30 interventional studies with no phase under Apraxias, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 99 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.